USA – FDA issues three guidances to expand cancer clinical trial eligibility

The US Food and Drug Administration’s (FDA) has issued a trio of draft guidance documents that aim to promote greater participation and diversity in...
FDA finalizes contentious guidance on third party 510(k) reviews

USA – FDA offers details on PDUFA VII STAR review pilot

The US Food and Drug Administration (FDA) has announced details on its Split Real Time Application Review (STAR) pilot, a program designed to shorten...

USA – Industry asks FDA to align quantitative labeling guidance with other regulators

Pharmaceutical manufacturers said the US Food and Drug Administration (FDA) draft guidance specifying quantitative labeling recommendations for sodium, potassium and phosphorus in human over-the-counter...

USA – FDA finalizes guidance on cannabis clinical research

The US Food and Drug Administration has finalized a 2020 draft guidance outlining how sponsors and investigators can conduct clinical trials for certain drugs...

USA – NCI official raises concerns about FDA’s cancer drug dose optimization guidance

The head of the National Cancer Institute’s (NCI) investigational drug research branch said that recent draft guidance from the US Food and Administration (FDA)...

USA – Accelerated approval trials: Commenters seek details on single-arm considerations

The US Food and Drug Administration (FDA) aimed to address some of the criticisms of its accelerated approval program with new draft guidance that...

USA – Patients with incurable cancer should be included in trials for new therapies

The US Food and Drug Administration (FDA) has issued final guidance on the inclusion of patients with incurable cancers in clinical trials for investigational...

USA – Pharma industry making some headway in DSCSA implementation

The pharmaceutical industry and its trading partners are making “some progress” in implementing the necessary systems to comply with the Drug Supply Chain Security Act (DSCSA),...

USA – FDA finalizes PK-based dosing guidance for PD-1/PD-L1 inhibitors

The US Food and Drug Administration (FDA) this week finalized guidance detailing how sponsors of programmed cell death receptor-1 (PD-1) and programmed cell death-ligand...

USA – Study: Extrapolation used in more than half of pediatric drug labeling changes

Some form of data extrapolation – either full or partial – was used in making more than 63% of pediatric labeling changes in the...

NOS PROCHAINES FORMATIONS